Related Experiment Video
Updated: Oct 26, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
MUSTARD-a comprehensive resource of mutation-specific therapies in cancer
Gauri Mittal1, Anu R I2,3, Aastha Vatsyayan4,5
1Indraprastha Institute of Information Technology, Okhla Industrial Estate, Phase III, Delhi 110020, India.
Abstract:
The steady increase in global cancer burden has fuelled the development of several modes of treatment for the disease. In the presence of an actionable mutation, targeted therapies offer a method to selectively attack cancer cells, increasing overall efficacy and reducing harmful side effects. However, different drug molecules are in different stages of development, with new molecules obtaining approvals from regulatory agencies each year. To augment clinical impact, it is important that this information reaches clinicians, patients and researchers swiftly and in a structured, well-annotated manner. To this end, we have developed Mutation-Specific Therapies Resource and Database in Cancer (MUSTARD), a database that is designed to be a centralized resource with diverse information such as cancer subtype, associated mutations, therapy offered and its effect observed, along with links to external resources for a more comprehensive annotation. In its current version, MUSTARD comprises over 2105 unique entries, including associations between 418 unique drug therapies, 189 cancer subtypes and 167 genes curated and annotated from over 862 different publications. To the best of our knowledge, it is the only resource that offers comprehensive information on mutation-specific, gene fusions and overexpressed gene-targeted therapies for cancer. Database URL: http://clingen.igib.res.in/mustard/.
Insights
The Mutation-Specific Therapies Resource and Database in Cancer (MUSTARD) centralizes information on targeted cancer therapies, mutations, and outcomes. This resource aids clinicians, patients, and researchers in accessing crucial data for cancer treatment decisions.
Area of Science:
- Oncology
- Bioinformatics
- Genomics
Background:
- The global cancer burden necessitates advanced treatment strategies.
- Targeted therapies offer efficacy against cancer cells with actionable mutations, minimizing side effects.
- Rapidly evolving drug development requires swift dissemination of information to stakeholders.
Purpose of the Study:
- To develop a centralized, structured, and well-annotated resource for mutation-specific cancer therapies.
- To facilitate access to diverse information including cancer subtypes, mutations, therapies, and outcomes.
- To augment the clinical impact of targeted cancer therapies.
Main Methods:
- Development of the Mutation-Specific Therapies Resource and Database in Cancer (MUSTARD).
- Curation and annotation of data from scientific publications.
- Integration of information on cancer subtypes, gene mutations, drug therapies, and observed effects.
Main Results:
- MUSTARD currently contains over 2105 unique entries.
- The database links 418 drug therapies, 189 cancer subtypes, and 167 genes.
- Data is curated from 862 publications, providing comprehensive annotations.
Conclusions:
- MUSTARD serves as a unique, centralized resource for mutation-specific, gene fusion, and overexpressed gene-targeted cancer therapies.
- The database enhances accessibility of critical information for cancer research and clinical practice.
- MUSTARD supports informed decision-making in personalized cancer treatment.
More Related Videos
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...